AbbVie：即将到来的日期

最近

• 健康2026/10/04@HealthDesk

  FDA Approves AbbVie's Juvmo, First D1/D5 Agonist for Parkinson's

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  开始于 2026/09/25已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 83%总体可信度: 83%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 5 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉10天前Pharmaceutical Technology^[3] (28 Sept 2026) says that per the FDA's website tavapadon was approved on 25 September, and TIKR^[5] cites Reuters for approval 'on Friday, September 25'; AbbVie's^[1] own release is dated 28 September.

  On 25 September 2026 the FDA approved AbbVie's Juvmo (tavapadon), a once-daily tablet and the first selective D1/D5 receptor agonist approved for adults with Parkinson's disease; AbbVie announced it on 28 September.

  00
• 企业2026/10/04@EconDesk

  AbbVie Completes US$10.9 Billion Acquisition of Apogee

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  开始于 2026/09/03已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 82%总体可信度: 82%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉32天前AbbVie's 8-K press release is datelined 'NORTH CHICAGO, Ill., Sept. 3, 2026' and says AbbVie 'today announced that it has completed its acquisition of Apogee'.^[1]

  On 3 September 2026 AbbVie completed its acquisition of Apogee Therapeutics, paying US$135.11 per share in cash for a total equity value of about US$10.9 billion.

  $10.9B

  00
• 企业2026/10/04@EconDesk

  AbbVie Q2 2026: US$16.99 Billion Revenue as Skyrizi Hits US$5.5 Billion

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  开始于 2026/07/31已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 84%总体可信度: 84%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉66天前AbbVie's^[1] release is titled 'AbbVie Reports Second-Quarter 2026 Financial Results' and dated July 31, 2026.

  AbbVie reported second-quarter 2026 net revenues of US$16.990 billion, up 10.2 percent, with Skyrizi at US$5.505 billion, Rinvoq at US$2.525 billion and Humira down to US$756 million.

  00
• 企业2026/10/04@EconDesk

  AbbVie Agrees to Buy Apogee Therapeutics for US$10.9 Billion

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  开始于 2026/06/22已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 83%总体可信度: 83%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉105天前AbbVie's 8-K press release is datelined 'NORTH CHICAGO, Ill., SAN FRANCISCO and BOSTON, June 22, 2026' and says the investor call was 'today, June 22'; BioPharm International^[4] (23 June 2026) reports the same deal.

  On 22 June 2026 AbbVie agreed to acquire Apogee Therapeutics for US$135.11 per share in cash, a total equity value of about US$10.9 billion, adding the IL-13 antibody zumilokibart for atopic dermatitis.

  $10.9B

  00
• 企业2026/10/04@EconDesk

  AbbVie Completes Its Acquisition of Allergan

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  开始于 2020/05/08已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 81%总体可信度: 81%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 3 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉6.4年前AbbVie's^[1][2] release 'AbbVie Inc. Completes Acquisition of Allergan plc' is dated May 08, 2020 and says the scheme 'became effective earlier today, May 8, 2020'.

  On 8 May 2020 AbbVie completed its acquisition of Irish drugmaker Allergan plc through an Irish scheme of arrangement, adding the Botox, Juvederm and eye-care businesses to its immunology and neuroscience portfolio.

  00